- November 16, 2016
- Posted by: cipcadmin
- Category: Events & Tradeshows, News Releases
West Vancouver, British Columbia, November 16, 2016 – Canadian International Pharma Corp. (the “Company” or “CIPC”) – CIPC is pleased to announce that it has engaged Bahrain Capital Group to assist in developing strategic Arab Gulf Region partnerships.
As a result of Bahrain Capital’s initial introductions, meetings have been arranged this month with H.R.H Prince Abdul Aziz Bin Abdullah Bin Saud of the Kingdom of Saudi Arabia, and also Sheikh Abdullah Al Khalifa of Bahrain. Dr. Mehrun Payravi, President of CIPC, will attend these meetings as part of an International trip planned for November. As well as these meetings, Dr. Payravi will travel to India to attend the CPhI trade show, to source from leading pharmaceutical ingredients and machinery suppliers, and will endeavour to meet with key government officials and supplier/manufacturers in India, Bahrain and Saudi Arabia.
The Company believes there are significant opportunities to establish joint ventures for the sale and production of medications in the Gulf region. The Gulf Cooperation Council (“GCC”) is a regional common market made up of 6 states including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and UAE.
As a result of the region’s growing youth population and a continued rise in expat workers, the Gulf’s dependence on world-class pharmaceuticals is growing significantly. The GCC is home to some of the highest levels of lifestyle disease with five of the six Gulf nations featuring in the top 10 countries in the world for the most prevalent levels of diabetes. Levels of heart disease are also high and the combination of increasing hereditary and lifestyle-related health problems indicate the region will demand an increasing supply of medicines over the coming decades.
About Bahrain Capital Group
The Bahrain Capital Group (BCG) is a dynamic private corporation with the overall vision for attracting investment into the Kingdom and financially supporting initiatives that enhance the investment climate.
The BCG works with the government and both current and prospective investors to ensure that Bahrain’s investment climate is attractive, to communicate the key strengths, and to identify where opportunities exist for further economic growth through investment.
About Canadian International Pharma Corp.
Canadian International Pharma Corp. (“CIPC” or the “Company”) is an emerging multi-faceted pharmaceutical company that is in the process of developing generic and nutraceutical drug manufacturing, distribution and sales. CIPC has recently launched its PharmaCert Program. PharmaCert is a certification program for testing and measuring finished dosage forms of nutraceutical and pharmaceutical medications. The Company has also aligned itself with Canadian and US manufacturers with the objective of manufacturing generics and nutraceuticals for Canadian and overseas markets.
For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit the Company’s website at www.canpharmacorp.ca.
CANADIAN INTERNATIONAL PHARMA CORP.
Mehrun Payravi, President
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy of accuracy of this release.
FORWARD LOOKING STATEMENTS
This release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable securities legislation. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “suspects”, “intends”, “estimates”, “projects”, ”targets”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those expressed in, or implied by, this forward looking information. Factors that could cause actual results to differ materially from those in forward-looking statements include such matters as market prices for the Company’s anticipated products, regulatory approvals required for the Company’s business plans, continued availability of capital and financing, and general economic, market or business conditions. Any forward-looking statements are expressly qualified in their entirety by this cautionary statement. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date such statements were made. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent an exemption from the registration requirements of such Act.